LINC01820: LINC01820 is an m6A-lncRNA that has been found to be closely correlated with poor prognosis in patients with kidney renal clear cell carcinoma (KIRC) [PMC8290079]. It has been identified as an independent factor associated with prognosis in KIRC [PMC8290079]. Although LINC01820 and LINC02257 do not regulate tumor behavior through the lncRNA-miRNA-mRNA pathway, they are connected to RNA-binding proteins [PMC8290079]. While there is no survival discrepancy between low and high expression of LINC01820, the m6AlRsPI model based on LINC02257 and LINC01820 shows that the high m6AlRsPI group has a poor prognosis [PMC8290079]. Currently, there are no articles reporting a correlation between LINC01820 and prognosis in other tumors [PMC8290079]. In KIRC cell lines, the expression level of LINC01820 is elevated compared to normal kidney cell lines [PMC8290079]. Although there is no survival discrepancy based on expression level of LINC01820, it is believed to be a prognosis-associated m6A-lncRNA based on the analysis results [PMC8290079]. The prognostic values of LINC01820 and m6AlRsPI have not been validated by external cohorts yet [PMC8290079]. The lncRNAs AC104964.1, SLC7A11-AS1, LINC00616, LINC01820, and AC110011.1 are located near protein-coding genes MSRA, SLC7A11, EPAS1, and DUSP1 in KIRC [PMC7516207]. Weighted co-expression network analysis has been used to select lncRNAs such as LINC02257 and LINC01820 for constructing a KIRC model and analyzing their potential prognostic value [PMC10031908].